5-(4-bromophenyl)morpholin-3-one | 1147392-80-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 5-(4-bromophenyl)morpholin-3-one
• CAS: 1147392-80-0
• 化学式: C₁₀H₁₀BrNO₂
• 分子量: 256.099
• InChiKey: ZTGHSKULYDVJHY-UHFFFAOYSA-N

物化性质

• 沸点：
  444.2±45.0 °C(Predicted)
• 密度：
  1.502±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-bromophenyl)morpholin-3-one 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 生成 3-(4-bromophenyl)morpholine
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1
• 作为产物：
  描述：

  N-[1-(4-bromophenyl)-2-hydroxyethyl]-2-chloroacetamide 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以1.6 g的产率得到5-(4-bromophenyl)morpholin-3-one
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1

文献信息

• [EN] BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] DÉRIVÉS DE BIPHÉNYLE COMME MODULATEURS DU RÉCEPTEUR H-3 DE L'HISTAMINE UTILES POUR LE TRAITEMENT DE TROUBLES SE RAPPORTANT À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2009058300A1

  公开（公告）日：2009-05-07

  Biphenyl derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the H3 histamine receptor. (Ia) Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness, such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.

  式(Ia)联苯衍生物及其调节H3组胺受体活性的药用组合物。本发明化合物及其药用组合物针对治疗与组胺H3受体相关的一系列疾病的方法，包括认知障碍、癫痫、脑创伤、抑郁症、肥胖症、睡眠与觉醒障碍，如嗜睡症、轮班工作综合征、药物副作用引起的嗜睡、保持警觉以帮助完成任务等、猝倒症、过度嗜睡、嗜睡综合征、时差反应、睡眠呼吸暂停等；注意力缺陷多动障碍(ADHD)、精神分裂症、过敏反应、上呼吸道过敏、过敏性鼻炎、鼻塞、痴呆、阿尔茨海默病、疼痛等。
• BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2217592A1

  公开（公告）日：2010-08-18
• [EN] HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS DE LA PROTÉASE 7 SPÉCIFIQUE DE L'UBIQUITINE
  申请人：[en]ALMAC DISCOVERY LIMITED

  公开号：WO2023139241A1

  公开（公告）日：2023-07-27

  The present invention concerns inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof. Specifically, the invention provides compounds according to formula (I), including stereoisomers, pharmaceutically acceptable salt or solvate thereof: